These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1471864)

  • 1. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease.
    Oertel WH; Tatsch K; Schwarz J; Kraft E; Trenkwalder C; Scherer J; Weinzierl M; Vogl T; Kirsch CM
    Ann Neurol; 1992 Dec; 32(6):743-8. PubMed ID: 1471864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.
    Oder W; Brücke T; Kollegger H; Spatt J; Asenbaum S; Deecke L
    J Neural Transm (Vienna); 1996; 103(8-9):1093-103. PubMed ID: 9013397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
    Tatsch K; Schwarz J; Oertel WH; Kirsch CM
    Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.
    Schwarz J; Antonini A; Kraft E; Tatsch K; Vogl T; Kirsch CM; Leenders KL; Oertel WH
    Neurology; 1994 Jun; 44(6):1079-82. PubMed ID: 8208404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms].
    Bettin S; Kämpfer I; Seese A; Schäfer A; Reuter M; Lössner J; Dietrich J; Wagner A; Knapp WH
    Nuklearmedizin; 1997 Aug; 36(5):167-72. PubMed ID: 9380528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
    Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.
    Schwarz J; Antonini A; Tatsch K; Kirsch CM; Oertel WH; Leenders KL
    Nucl Med Commun; 1994 Oct; 15(10):806-13. PubMed ID: 7838444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
    Ichise M; Toyama H; Fornazzari L; Ballinger JR; Kirsh JC
    J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
    Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
    Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
    Volk S; Maul FD; Hör G; Schreiner M; Weppner M; Holzmann T; Pflug B
    Psychiatry Res; 1994 Jun; 55(2):111-8. PubMed ID: 10711799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological and functional imaging in neurological and non-neurological Wilson's patients.
    Hermann W
    Ann N Y Acad Sci; 2014 May; 1315():24-9. PubMed ID: 24495036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability.
    Verhoeff NP; Kapucu O; Sokole-Busemann E; van Royen EA; Janssen AG
    J Nucl Med; 1993 Dec; 34(12):2076-84. PubMed ID: 8254390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.
    Abi-Dargham A; Kegeles LS; Zea-Ponce Y; Mawlawi O; Martinez D; Mitropoulou V; O'Flynn K; Koenigsberg HW; Van Heertum R; Cooper T; Laruelle M; Siever LJ
    Biol Psychiatry; 2004 May; 55(10):1001-6. PubMed ID: 15121484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study.
    Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Murray RM; Kerwin RW
    Br J Psychiatry; 1994 Jan; 164(1):16-26. PubMed ID: 8137105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
    van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG
    Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.